Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
6.38
-0.06 (-0.93%)
At close: Dec 5, 2025, 4:00 PM EST
6.44
+0.06 (0.94%)
After-hours: Dec 5, 2025, 7:53 PM EST
Aquestive Therapeutics Employees
Aquestive Therapeutics had 142 employees as of December 31, 2024. The number of employees increased by 7 or 5.19% compared to the previous year.
Employees
142
Change (1Y)
7
Growth (1Y)
5.19%
Revenue / Employee
$305,613
Profits / Employee
-$485,768
Market Cap
778.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AQST News
- 4 weeks ago - Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development Transcript - Seeking Alpha
- 4 weeks ago - Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET - GlobeNewsWire
- 7 weeks ago - Aquestive Therapeutics: A Measured Bet - Seeking Alpha
- 2 months ago - Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ - GlobeNewsWire
- 3 months ago - Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst - Seeking Alpha
- 4 months ago - Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 4 months ago - Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film - GlobeNewsWire